Prax­is stock tanks af­ter mid-stage move­ment dis­or­der tri­al miss

Prax­is Pre­ci­sion Med­i­cines has missed its goal in a Phase IIb tri­al af­ter rolling out pos­i­tive Phase IIa re­sults last year.

The CNS-fo­cused biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.